Investigational approaches for unmet need in severe asthma

References

• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343.
   PubMed Web of Science ®Google Scholar
• Jørgensen IM, Jensen VB, Bülow S, et al. Asthma mortality in the Danish child population: risk factors and causes of asthma death. Pediatr Pulmonol. 2003;36(2):142–147. Epub 2003/07/02. PubMed PMID: 12833494.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388–395. Epub 2009/06/02. PubMed PMID: 19483109; PubMed Central PMCID: PMCPMC2742757
   PubMed Web of Science ®Google Scholar
• Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218–224. Epub 2008/05/16. PubMed PMID: 18480428; PubMed Central PMCID: PMCPMC3992366.
   PubMed Web of Science ®Google Scholar
• Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181(4):315–323. Epub 2009/11/05. PubMed PMID: 19892860.
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005;115(2):233–242. Epub 2005/02/08. PubMed PMID: 15696076.
   PubMed Web of Science ®Google Scholar
• Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax. 2007;62(12):1043–1049. Epub 2007/03/13. PubMed PMID: 17356056.
   PubMed Web of Science ®Google Scholar
• The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003, 22(3):470–477. Epub 2003/10/01. Epub 2003/10/01. https://pubmed.ncbi.nlm.nih.gov/14516137/.
   PubMed Web of Science ®Google Scholar
• Lieberman P, Patterson R, Kunske R.Complications of long-term steroid therapy for asthma. J Allergy Clin Immunol. 1972;49(6):329–336; Epub 1972/06/01. PubMed PMID: 5025095.
   PubMed Web of Science ®Google Scholar
• Schäcke H, Döcke WD, Asadullah K.Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23–43; Epub 2002/11/21. PubMed PMID: 12441176.
   PubMed Web of Science ®Google Scholar
• USFaD A Novel drug approvals for 2015: Food and Drug Administration; 2020, cited 2020 Dec 30. Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2015.
   Google Scholar
• USFaD A Novel drug approvals for 2016: Food and Drug Administration; 2018 cited 2020 Dec 30. Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2016.
   Google Scholar
• USFaD A Novel drug approvals for 2017: Food and Drug Administration; 2017 cited 2020 Dec 30. Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017.
   Google Scholar
• USFaD A New drug therapy approvals 2019: Food and Drug Administration; 2020 cited 2020 Dec 30. Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2019.
   Google Scholar
• USFaD A FDA approves maintenance treatment for severe asthma (Tezepelumab) 2021 cited 2022 Jan 5. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-maintenance-treatment-severe-asthma.
   Google Scholar
• Casale TB, Pacou M, Mesana L, et al.Reslizumab compared with benralizumab in patients with eosinophilic asthma: a systematic literature review and network meta-analysis. J Allergy Clin Immunol Pract. 2019;7(1):122–30.e1; Epub 2018/09/16. PubMed PMID: 30217529.
   PubMed Web of Science ®Google Scholar
• NICE. Benralizumab for treating severe eosinophilic asthma: NICE. 2019. updated 03 Sept 2019; cited 2019; cited 2020 Sept 2019; cited 2020 6th May 03 Sept 2019; cited 2020 6th. Available from: https://www.nice.org.uk/guidance/ta565/chapter/1-Recommendations.
   Google Scholar
• NICE. Mepolizumab for treating severe refractory eosinophilic asthma NICE: NICE; 2017 updated 25 Jan 2017; cited 2017; cited 2020 Jan 2017; cited 2020 6th May 25 Jan 2017; cited 2020 6th. Available from: https://www.nice.org.uk/guidance/TA431/chapter/1-Recommendations.
   Google Scholar
• NICE. Omalizumab for treating severe persistent allergic asthma nice.org.uk: NICE; 2013 [cited 2020 6th May]. Available from: https://www.nice.org.uk/guidance/ta278/chapter/3-The-technology.
   Google Scholar
• NICE. Reslizumab for treating severe eosinophilic asthma nice.org.uk: NICE; 2020 cited 2020 May 6th. Available from: https://www.nice.org.uk/guidance/TA479/chapter/1-Recommendations.
   Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2021. [cited 2022 Jan, 12]. Available from: www.ginasthma.org.
   Google Scholar
• Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59–99. Epub 2009/06/19. PubMed PMID: 19535666.
   PubMed Web of Science ®Google Scholar
• Fuhlbrigge A, Peden D, Apter AJ, et al. Asthma outcomes: exacerbations. J Allergy Clin Immunol. 2012;129(3 Suppl):S34–48. Epub 2012/03/14. PubMed PMID: 22386508; PubMed Central PMCID:PMCPMC3595577.
   PubMed Web of Science ®Google Scholar
• Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol.2001;107(1):3–8. Epub 2001/01/10. PubMed PMID: 11149982.
   PubMed Web of Science ®Google Scholar
• Agency USEP. Asthma Facts 2013 cited 2020 Oct 11. Available from: http://www.epa.gov/asthma/pdfs/asthma_fact_sheet_en.pdf.
   Google Scholar
• Barnett SB, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007. J Allergy Clin Immunol.2011;127(1):145–152. Epub 2011/01/08. PubMed PMID: 21211649.
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children Cochrane Database Syst Rev 20141 Cd003559 Epub 2014/01/15. https://doi.org/10.1002/14651858.CD003559.pub4. PubMed PMID: 24414989
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2019;1900588. https://doi.org/10.1183/13993003.00588-2019.
   Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. Epub 2017/04/12. PubMed PMID: 28395936.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. Epub 2014/09/10. PubMed PMID: 25199060.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, et al.Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 Study.Chest.2016;150(4):789–798. Epub 2016/04/09. PubMed PMID: 27056586.
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–1132. Epub 2011/08/20. PubMed PMID: 21852542.
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. Epub 2015/03/05. PubMed PMID: 25736990.
   PubMed Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, et al.Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts.Chest.2016;150(4):799–810. Epub 2016/03/29. PubMed PMID: 27018175.
   PubMed Web of Science ®Google Scholar
• Park HS, Kim MK, Imai N, et al. A phase 2a study of benralizumab for patients with eosinophilic Asthma in South Korea and Japan. Int Arch Allergy Immunol. 2016;169(3):135–145. Epub 2016/04/21. PubMed PMID: 27097165.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. Epub 2016/09/10. PubMed PMID: 27609408.
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–890. Epub 2014/10/13. PubMed PMID: 25306557.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. Epub 2016/09/10. PubMed PMID: 27609406.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. Epub 2017/05/23. PubMed PMID: 28530840.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496.
   PubMed Web of Science ®Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936–946.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809.
   PubMed Web of Science ®Google Scholar
• Chung LP, Upham JW, Bardin PG, et al. Rational oral corticosteroid use in adult severe asthma: a narrative review. Respirology. 2020;25(2):161–172. Epub 2019/11/12. PubMed PMID: 31713955.
   PubMed Web of Science ®Google Scholar
• Suehs CM, Menzies-Gow A, Price D, et al. Expert consensus on the tapering of oral corticosteroids for the treatment of asthma. a Delphi study. Am J Respir Crit Care Med. 2021;203(7):871–881. Epub 2020/10/29. PubMed PMID: 33112646.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022;10(1):47–58. Epub 2021/10/08. PubMed PMID: 34619104.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Michils A, Louis R, et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med. 2009;103(11):1633–1642. Epub 2009/07/22. PubMed PMID: 19619998.
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Virchow JC, Murphy K, et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2020;8(5):461–474. Epub 2020/02/19. PubMed PMID: 32066536.
   PubMed Web of Science ®Google Scholar
• Study to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma (SOURCE). 2021.
   Google Scholar
• Kelsen SG, Agache IO, Soong W, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial. J Allergy Clin Immunol. 2021;148(3):790–798. Epub 2021/04/20. PubMed PMID: 33872652.
   PubMed Web of Science ®Google Scholar
• Peters MC, Fahy JV.Metabolic consequences of obesity as an “outside in” mechanism of disease severity in asthma. Eur Respir J. 2016;48(2):291–293. Epub 2016/08/02. PubMed PMID: 27478182
   PubMedGoogle Scholar
• Cowan DC, Cowan JO, Palmay R, et al. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax. 2010;65(5):384.
   PubMed Web of Science ®Google Scholar
• Pelosi P, Croci M, Ravagnan I, et al.Total respiratory system, lung, and chest wall mechanics in sedated-paralyzed postoperative morbidly obese patients. Chest. 1996;109(1):144–151. Epub 1996/01/01. PubMed PMID: 8549177.
   PubMed Web of Science ®Google Scholar
• Locksley RM.Asthma and allergic inflammation. Cell. 2010;140(6):777–783. Epub 2010/03/23. PubMed PMID: 20303868; PubMed Central PMCID: PMCPMC3134388.
   PubMedGoogle Scholar
• Corry DB, Folkesson HG, Warnock ML, et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med. 1996;183(1):109–117. PubMed PMID: 8551213.
   PubMed Web of Science ®Google Scholar
• Persson EK, Verstraete K, Heyndrickx I, et al. Protein crystallization promotes type 2 immunity and is reversible by antibody treatment. Science. 2019;364(6442): Epub 2019/05/28. https://doi.org/10.1126/science.aaw4295. PubMed PMID: 31123109.
   Google Scholar
• Georas SN, Wright RJ, Ivanova A, et al. The precision interventions for severe and/or exacerbation-prone (precise) asthma network: an overview of network organization, procedures, and interventions. J Allergy Clin Immunol. 2021. Epub 2021/12/02. https://doi.org/10.1016/j.jaci.2021.10.035. PubMed PMID: 34848210.
   Google Scholar
• Beyond allergic Th2 (BEAT severe asthma, BEAT-SA): University of Leicester; cited 2022 Feb 5. Available from: https://le.ac.uk/lctu/trials/beat-severe-asthma.
   Google Scholar
• Beat Severe Asthma ISRCTN57935812 updated Sept 10th, 2021; cited 2021; cited 2022 Sept 10th, 2021; cited 2022 Feb 10th, 2021; cited 2022 Feb 5th. Available from: https://www.isrctn.com/ISRCTNISRCTN57935812.
   Google Scholar
• Perez T, Chanez P, Dusser D, et al.Prevalence and reversibility of lung hyperinflation in adult asthmatics with poorly controlled disease or significant dyspnea. Allergy. 2016;71(1):108–114; Epub 2015/10/16. PubMed PMID: 26466328.
   PubMedGoogle Scholar
• Naqvi M, Thyne S, Choudhry S, et al. Ethnic-specific differences in bronchodilator responsiveness among African Americans, Puerto Ricans, and Mexicans with asthma. J Asthma. 2007;44(8):639–648. Epub 2007/10/19. PubMed PMID: 17943575.
   PubMed Web of Science ®Google Scholar
• Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000;162(1):75–80. Epub 2000/07/21. PubMed PMID: 10903223.
   PubMed Web of Science ®Google Scholar
• Green SA, Turki J, Innis M, et al.Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994;33(32):9414–9419. Epub 1994/08/16. PubMed PMID: 7915137
   PubMed Web of Science ®Google Scholar
• Contopoulosioannidis DG, Manoli EN, Ioannidis JP.Meta-analysis of the association of β2-adrenergic receptor polymorphisms with asthma phenotypes. J Allergy Clin Immunol. 2005;115(5):963–972. Epub 2005/05/04. PubMed PMID: 15867853.
   PubMedGoogle Scholar
• Gaston B, Reilly J, Drazen JM, et al. Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci U S A. 1993;90(23):10957–10961. PubMed PMID: 8248198.
   PubMedGoogle Scholar
• Gaston B, Sears S, Woods J, et al. Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure. Lancet. 1998;351(9112):1317–1319. Epub 1998/06/27. PubMed PMID: 9643794.
   PubMed Web of Science ®Google Scholar
• Que LG, Yang Z, Stamler JS, et al.S-nitrosoglutathione reductase: an important regulator in human asthma. Am J Respir Crit Care Med. 2009;180(3):226–231; Epub 2009/04/28. PubMed PMID: 19395503; PubMed Central PMCID: PMCPMC2724715.
   PubMed Web of Science ®Google Scholar
• Whalen EJ, Foster MW, Matsumoto A, et al. Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell. 2007;129(3):511–522. Epub 2007/05/08. PubMed PMID: 17482545.
   PubMed Web of Science ®Google Scholar
• Que LG, Liu L, Yan Y, et al. Protection from experimental asthma by an endogenous bronchodilator. Science. 2005;308(5728):1618–1621. Epub 2005/05/28. PubMed PMID: 15919956; PubMed Central PMCID: PMCPMC2128762.
   PubMed Web of Science ®Google Scholar
• Wu H, Romieu I, Sienra-Monge JJ, et al. Genetic variation in S-nitrosoglutathione reductase (GSNOR) and childhood asthma. J Allergy Clin Immunol. 2007;120(2):322–328. Epub 2007/06/05. PubMed PMID: 17543375; PubMed Central PMCID: PMCPMC2094003.
   PubMedGoogle Scholar
• Choudhry S, Que LG, Yang Z, et al. GSNO reductase and beta2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol. Pharmacogenet Genomics. 2010;20(6):351–358. PubMed PMID: 20335826
   PubMed Web of Science ®Google Scholar
• Marozkina NV, Wang XQ, Stsiapura V, et al. Phenotype of asthmatics with increased airway S-nitrosoglutathione reductase activity. Eur Respir J. 2015;45(1):87–97. Epub 2014/11/02. PubMed PMID: 25359343; PubMed Central PMCID: PMCPMC4283933
   PubMedGoogle Scholar
• Carraro S, Palmer L, and DeRonde K, et al. editors. Upregulation of the asthma enzyme, S-nitrosoglutathione reductase, by interleukin 13. Proc Am Thorac Soc. American Thoracic Society; 2006.
   Google Scholar
• Greenwald R, Fitzpatrick AM, Gaston B, et al. Breath formate is a marker of airway S-nitrosothiol depletion in severe asthma. PLoS One. 2010;5(7):11919. Epub 2010/08/07. PubMed PMID: 20689836; PubMed Central PMCID: PMCPMC2912922.
   Google Scholar
• Tupper OD, Ulrik CS. Long-term predictors of severe exacerbations and mortality in a cohort of well-characterised adults with asthma. Respir Res. 2021;22(1):269. PubMed PMID: 34670588.
   PubMedGoogle Scholar
• Berger P, Scotto-Gomez E, Molimard M, et al. Omalizumab decreases nonspecific airway hyperresponsiveness in vitro. Allergy. 2007;62(2):154–161. Epub 2007/02/15. PubMed PMID: 17298424.
   PubMedGoogle Scholar
• Calzetta L, Ritondo BL, Matera MG, et al. Targeting IL-5 pathway against airway hyperresponsiveness: a comparison between benralizumab and mepolizumab. Br J Pharmacol. 2020;177(20):4750–4765. Epub 2020/09/17. PubMed PMID: 32857420.
   PubMed Web of Science ®Google Scholar
• Dupilumab on airway hyper-responsiveness and ventilation heterogeneity in patients with asthma. NCT03884842. 2021; [ cited 2022 30th January].
   Google Scholar
• Sverrild A, Bergqvist A, Baines KJ, et al. Airway responsiveness to mannitol in asthma is associated with chymase-positive mast cells and eosinophilic airway inflammation. Clin Exp Allergy. 2016;46(2):288–297. Epub 2015/08/08. PubMed PMID: 26252943.
   PubMedGoogle Scholar
• Gibson PG, Saltos N, Borgas T. Airway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroid-treated asthma. J Allergy Clin Immunol. 2000;105(4):752–759. Epub 2000/04/11. PubMed PMID: 10756226.
   PubMed Web of Science ®Google Scholar
• Siddiqui S, Mistry V, Doe C, et al. Airway hyperresponsiveness is dissociated from airway wall structural remodeling. J Allergy Clin Immunol. 2008;122(2):335–41.e3413. Epub 2008/06/24. PubMed PMID: 18572228.
   PubMedGoogle Scholar
• Balzar S, Fajt ML, Comhair SA, et al. Mast cell phenotype, location, and activation in severe asthma. Data from the severe asthma research program. Am J Respir Crit Care Med. 2011;183(3):299–309. Epub 2010/09/04. PubMed PMID: 20813890; PubMed Central PMCID: PMCPMC3056228.
   PubMed Web of Science ®Google Scholar
• Bradding P, Walls AF, Holgate ST.The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol. 2006;117(6):1277–1284. Epub 2006/06/06. PubMed PMID: 16750987
   PubMed Web of Science ®Google Scholar
• Da Silva CA, Reber L, Frossard N. Stem cell factor expression, mast cells and inflammation in asthma. Fundam Clin Pharmacol. 2006;20(1):21–39; Epub 2006/02/02. PubMed PMID: 16448392.
   PubMedGoogle Scholar
• Cahill KN, Katz HR, Cui J, et al. KIT inhibition by imatinib in patients with severe refractory asthma. N Engl J Med. 2017;376(20):1911–1920.
   PubMed Web of Science ®Google Scholar
• Chanez P, Israel E, Davidescu L, et al. Masitinib significantly decreases the rate of asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids: a phase 3 multicenter study. B93 Late breaking clinical trials in airway diseases. American Thoracic Society International Conference Abstracts: American Thoracic Society; 2020. p. 4210–A.
   Google Scholar
• Davidescu L, Chanez P, Ursol G, et al. Late breaking abstract – masitinib in severe asthma: results from a randomized, phase 3 trial. Eur Respir J. 2020;56(64):4612.
   Google Scholar
• Humbert M, de Blay F, Garcia G, et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy. 2009;64(8):1194–1201. Epub 2009/07/21. PubMed PMID: 19614621.
   PubMed Web of Science ®Google Scholar
• Sverrild A, Hansen S, Hvidtfeldt M, et al. The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). Eur Respir J. 2022;59(1):2101296.
   PubMedGoogle Scholar
• Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299–1312. Epub 2021/07/14. PubMed PMID: 34256031.
   PubMed Web of Science ®Google Scholar
• Bumbacea D, Campbell D, Nguyen L, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J. 2004;24(1):122–128. Epub 2004/08/06. PubMed PMID: 15293614.
   PubMed Web of Science ®Google Scholar
• Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from prospero, a prospective real-world study. J Allergy Clin Immunol Pract. 2019;7(1):156–641. Epub 2018/05/26. PubMed PMID: 29800752.
   PubMed Web of Science ®Google Scholar
• Dunnill MS.The pathology of asthma, with special reference to changes in the bronchial mucosa. J Clin Pathol. 1960;13(1):27–33. Epub 1960/01/01. PubMed PMID: 13818688; PubMed Central PMCID: PMCPMC479992.
   PubMed Web of Science ®Google Scholar
• Dunican EM, Elicker BM, Gierada DS, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128(3):997–1009. Epub 2018/02/06. PubMed PMID: 29400693; PubMed Central PMCID: PMCPMC5824874.
   PubMed Web of Science ®Google Scholar
• Hearn APM MS, Budaj I, and Qurashi N, et al. Clinical characteristics associated with mucus plugging in severe eosinophilic asthma and the effectiveness of benralizumab treatment. London: British Thoracic Society Winter Meeting 2021: Thorax; 2021. p. 54.
   Google Scholar
• Ehre C, Rushton ZL, Wang B, et al. An improved inhaled mucolytic to treat airway muco-obstructive diseases. Am J Respir Crit Care Med. 2019;199(2):171–180. Epub 2018/09/14. PubMed PMID: 30212240; PubMed Central PMCID: PMCPMC6353008.
   PubMedGoogle Scholar
• Kuperman DA, Huang X, Koth LL, et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med. 2002;8(8):885–889. Epub 2002/07/02. PubMed PMID: 12091879.
   PubMed Web of Science ®Google Scholar
• Lachowicz-Scroggins ME, Yuan S, Kerr SC, et al. Abnormalities in MUC5AC and MUC5B protein in airway mucus in asthma. Am J Respir Crit Care Med. 2016;194(10):1296–1299. PubMed PMID: 27845589.
   PubMedGoogle Scholar
• Gleich GJ, Loegering DA, Mann KG, et al. Comparative properties of the Charcot-Leyden crystal protein and the major basic protein from human eosinophils. J Clin Invest. 1976;57(3):633–640. PubMed PMID: 942977.
   PubMedGoogle Scholar
• Yuan S, Hollinger M, Lachowicz-Scroggins ME, et al. Oxidation increases mucin polymer cross-links to stiffen airway mucus gels. Sci Transl Med. 2015;7(276):276ra27. Epub 2015/02/27. PubMed PMID: 25717100; PubMed Central PMCID: PMCPMC4403633.
   PubMed Web of Science ®Google Scholar
• Jatakanon A, Uasuf C, Maziak W, et al.Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1532–1539. Epub 1999/11/11. PubMed PMID: 10556116.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Szefler SJ, Leung DY, et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med. 1997;156(3 Pt 1):737–743. Epub 1997/10/06. PubMed PMID: 9309987
   PubMed Web of Science ®Google Scholar
• Djukanović R, Homeyard S, Gratziou C, et al. The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation. Am J Respir Crit Care Med. 1997;155(3):826–832.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Khashayar R, Lazarus SC, et al. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol. 2001;108(5):753–758. Epub 2001/11/03. PubMed PMID: 11692100.
   PubMed Web of Science ®Google Scholar
• Busacker A, Newell JD Jr., Keefe T, et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest. 2009;135(1):48–56. Epub 2008/08/08. PubMed PMID: 18689585.
   PubMed Web of Science ®Google Scholar
• Chalmers GW, MacLeod KJ, Thomson L, et al. Smoking and airway inflammation in patients with mild asthma. Chest. 2001;120(6):1917–1922. Epub 2001/12/18. PubMed PMID: 11742922.
   PubMed Web of Science ®Google Scholar
• Baines KJ, Simpson JL, Wood LG, et al. Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. J Allergy Clin Immunol. 2011;127(1):153–60, 60.e1–9. Epub 2011/01/08. PubMed PMID: 21211650
   Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24(2):179–189; Epub 2006/02/14. PubMed PMID: 16473830.
   PubMed Web of Science ®Google Scholar
• Al-Ramli W, Prefontaine D, Chouiali F, et al. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol. 2009;123(5):1185–1187. Epub 2009/04/14. PubMed PMID: 19361847.
   PubMed Web of Science ®Google Scholar
• Nakae S, Komiyama Y, Nambu A, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity. 2002;17(3):375–387. Epub 2002/10/02. PubMed PMID: 12354389.
   PubMed Web of Science ®Google Scholar
• Linden A. Role of interleukin-17 and the neutrophil in asthma. Int Arch Allergy Immunol. 2001;126(3):179–184. Epub 2001/12/26. PubMed PMID: 11752873.
   PubMed Web of Science ®Google Scholar
• McKinley L, Alcorn JF, Peterson A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol. 2008;181(6):4089–4097. Epub 2008/09/05. PubMed PMID: 18768865; PubMed Central PMCID: PMCPMC3638757.
   PubMed Web of Science ®Google Scholar
• Lajoie S, Lewkowich IP, Suzuki Y, et al. Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat Immunol. 2010;11(10):928–935. Epub 2010/08/31. PubMed PMID: 20802484; PubMed Central PMCID: PMCPMC2943538.
   PubMed Web of Science ®Google Scholar
• Murdock BJ, Shreiner AB, McDonald RA, et al. Coevolution of TH1, TH2, and TH17 responses during repeated pulmonary exposure to Aspergillus fumigatus conidia. Infect Immun. 2011;79(1):125–135. Epub 2010/11/03. PubMed PMID: 21041495; PubMed Central PMCID: PMCPMC3019910.
   PubMedGoogle Scholar
• Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11):1294–1302. Epub 2013/11/10. PubMed PMID: 24200404.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Nair P, Cousins DJ, et al. Risankizumab in severe asthma – a phase 2a, placebo-controlled trial. N Engl J Med. 2021;385(18):1669–1679.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Metev H, Puu M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2016;4(10):797–806. Epub 2016/08/31. PubMed PMID: 27574788.
   PubMed Web of Science ®Google Scholar
• Wood LG, Simpson JL, Hansbro PM, et al. Potentially pathogenic bacteria cultured from the sputum of stable asthmatics are associated with increased 8-isoprostane and airway neutrophilia. Free Radic Res.2010;44(2):146–154. Epub 2009/11/20. PubMed PMID: 19922242.
   PubMed Web of Science ®Google Scholar
• Essilfie AT, Simpson JL, Horvat JC, et al. Haemophilus influenzae infection drives IL-17-mediated neutrophilic allergic airways disease. PLoS Pathog. 2011;7(10):e1002244. Epub 2011/10/15. PubMed PMID: 21998577; PubMed Central PMCID: PMCPMC3188527.
   PubMed Web of Science ®Google Scholar
• Green BJ, Wiriyachaiporn S, Grainge C, et al. Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma. PLoS One. 2014;9(6):100645. Epub 2014/06/24. PubMed PMID: 24955983; PubMed Central PMCID: PMCPMC4067344.
   PubMed Web of Science ®Google Scholar
• Huang YJ, Nariya S, Harris JM, et al. The airway microbiome in patients with severe asthma: associations with disease features and severity. J Allergy Clin Immunol. 2015;136(4):874–884. Epub 2015/07/30. PubMed PMID: 26220531; PubMed Central PMCID: PMCPMC4600429.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659–668. Epub 2017/07/09. PubMed PMID: 28687413.
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322–329. Epub 2013/01/08. PubMed PMID: 23291349.
   PubMed Web of Science ®Google Scholar
• Agency EM Bacterial lysates-containing medicinal products indicated for respiratory conditions EMA/502527/2019: European Medicines Agency; 2019 [updated 16th Sept 2019; cited 2022 8th Jan]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions.
   Google Scholar
• Schaad UB.OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review.World J Pediatr.2010;6(1):5–12. Epub 2010/02/10. PubMed PMID: 20143206.
   PubMed Web of Science ®Google Scholar
• Strickland DH, Judd S, Thomas JA, et al. Boosting airway T-regulatory cells by gastrointestinal stimulation as a strategy for asthma control. Mucosal Immunol.2011;4(1):43–52. Epub 2010/07/30. PubMed PMID: 20668438.
   PubMed Web of Science ®Google Scholar
• Navarro S, Cossalter G, Chiavaroli C, et al. The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. Mucosal Immunol. 2011;4(1):53–65. Epub 2010/09/03. PubMed PMID: 20811345.
   PubMed Web of Science ®Google Scholar
• Emeryk A, Bartkowiak-Emeryk M, Raus Z, et al. Mechanical bacterial lysate administration prevents exacerbation in allergic asthmatic children – the EOLIA study. Pediatr Allergy Immunol. 2018;29(4):394–401. Epub 2018/03/27. PubMed PMID: 29575037.
   PubMedGoogle Scholar
• Camargo CA Jr, Weiss ST, Zhang S, et al. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med. 1999;159(21):2582–2588.
   PubMedGoogle Scholar
• Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med. 2007;175(7):661–666. PubMed PMID: PMC1899288.
   PubMed Web of Science ®Google Scholar
• Moreira A, Bonini M, Garcia-Larsen V, et al. Weight loss interventions in asthma: EAACI evidence-based clinical practice guideline (part I). Allergy. 2013;68(4):425–439. Epub 2013/03/05. PubMed PMID: 23452010.
   PubMed Web of Science ®Google Scholar
• Schatz M, Zeiger RS, Zhang F, et al.Overweight/obesity and risk of seasonal asthma exacerbations.J Allergy Clin Immunol Pract.2013;1(6):618–622. Epub 2014/02/26. PubMed PMID: 24565709.
   PubMedGoogle Scholar
• Quinto KB, Zuraw BL, Poon KY, et al. The association of obesity and asthma severity and control in children. J Allergy Clin Immunol. 2011;128(5):964–969. Epub 2011/08/09. PubMed PMID: 21820711.
   PubMed Web of Science ®Google Scholar
• Dixon AE, Holguin F, Sood A, et al. An official American thoracic society workshop report: obesity and asthma. Proc Am Thorac Soc. 2010;7(5):325–335. Epub 2010/09/17. PubMed PMID: 20844291.
   PubMedGoogle Scholar
• Mosen DM, Schatz M, Magid DJ, et al. The relationship between obesity and asthma severity and control in adults. J Allergy Clin Immunol. 2008;122(3):507–116. Epub 2008/09/09. PubMed PMID: 18774387.
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Tsugawa Y, Lopez BL, et al. Body mass index and risk of hospitalization among adults presenting with asthma exacerbation to the emergency department. Ann Am Thorac Soc. 2014;11(9):1439–1444. Epub 2014/10/15. PubMed PMID: 25314160.
   PubMedGoogle Scholar
• Peters-Golden M, Swern A, Bird SS, et al. Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006;27(3):495.
   PubMed Web of Science ®Google Scholar
• Boulet LP, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med. 2007;101(11):2240–2247. Epub 2007/08/10. PubMed PMID: 17686624.
   PubMed Web of Science ®Google Scholar
• Sutherland ER, Goleva E, Strand M, et al. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med. 2008;178(7):682–687. Epub 2008/07/19. PubMed PMID: 18635892; PubMed Central PMCID: PMCPMC2556450.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Kohno N, Fujino S, et al. Circulating interleukin-6 levels in patients with bronchial asthma. Am J Respir Crit Care Med. 1995;151(5):1354–1358. Epub 1995/05/01. PubMed PMID: 7735584.
   PubMed Web of Science ®Google Scholar
• Peters MC, McGrath KW, Hawkins GA, et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med. 2016;4(7):574–584. Epub 2016/06/11. PubMed PMID: 27283230; PubMed Central PMCID: PMCPMC5007068.
   PubMed Web of Science ®Google Scholar
• Tillie-Leblond I, Pugin J, Marquette CH, et al. Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus. Am J Respir Crit Care Med. 1999;159(2):487–494. Epub 1999/02/02. PubMed PMID: 9927362.
   PubMed Web of Science ®Google Scholar
• Peters MC, Mauger D, Ross KR, et al. Evidence for exacerbation-prone asthma and predictive biomarkers of exacerbation frequency. Am J Respir Crit Care Med. 2020;202(7):973–982. Epub 2020/06/02. PubMed PMID: 32479111; PubMed Central PMCID: PMCPMC7528796.
   PubMed Web of Science ®Google Scholar
• Peters MC, Ringel L, Dyjack N, et al. A transcriptomic method to determine airway immune dysfunction in t2-high and t2-low asthma. Am J Respir Crit Care Med. 2019;199(4):465–477. Epub 2018/10/30. PubMed PMID: 30371106; PubMed Central PMCID: PMCPMC6376622.
   PubMed Web of Science ®Google Scholar
• Dienz O, Rincon M. The effects of IL-6 on CD4 T cell responses. Clin Immunol. 2009;130(1):27–33. Epub 2008/10/11. PubMed PMID: 18845487; PubMed Central PMCID: PMCPMC2660866.
   PubMed Web of Science ®Google Scholar
• Massoud AH, Charbonnier LM, Lopez D, et al. An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17-like cells. Nat Med. 2016;22(9):1013–1022. Epub 2016/08/02. PubMed PMID: 27479084; PubMed Central PMCID: PMCPMC5014738.
   PubMed Web of Science ®Google Scholar
• NICE guideline [NG191]. COVID-19 rapid guideline: managing COVID-19 national institute for health and clinical excellence. 2021 updated 16th Dec 2021; cited 2021; cited 2022 Dec 2021; cited 2022 Jan 16th Dec 2021; cited 2022 Jan 22nd. Available from: https://www.nice.org.uk/guidance/ng191/chapter/Recommendations
   Google Scholar
• Ferreira MA, Matheson MC, Duffy DL, et al. Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet. 2011;378(9795):1006–1014. Epub 2011/09/13. PubMed PMID: 21907864; PubMed Central PMCID: PMCPMC3517659.
   PubMed Web of Science ®Google Scholar
• Adikusuma W, Chou WH, Lin MR, et al. Identification of druggable genes for asthma by integrated genomic network analysis. Biomedicines. 2022;10(1):113. Epub 2022/01/22. PubMed PMID: 35052792.
   PubMedGoogle Scholar
• Ullah MA, Revez JA, Loh Z, et al. Allergen-induced IL-6 trans-signaling activates γδ T cells to promote type 2 and type 17 airway inflammation. J Allergy Clin Immunol. 2015;136(4):1065–1073. Epub 2015/05/02. PubMed PMID: 25930193.
   PubMed Web of Science ®Google Scholar
• Chen S, Chen Z, Deng Y, et al. Prevention of IL-6 signaling ameliorates toluene diisocyanate-induced steroid-resistant asthma. Allergol Int. 2022;71(1):73–82. Epub 2021/08/02. PubMed PMID: 34332882.
   PubMedGoogle Scholar
• Revez JA, Bain LM, Watson RM, et al. Effects of interleukin-6 receptor blockade on allergen-induced airway responses in mild asthmatics. Clin Transl Immunology. 2019;8(6):1044. Epub 2019/06/22. PubMed PMID: 31223480; PubMed Central PMCID: PMCPMC6566140.
   Google Scholar
• Esty B, Harb H, Bartnikas LM, et al. Treatment of severe persistent asthma with IL-6 receptor blockade. The Journal of Allergy and Clinical Immunology in Practice. 2019;7(5):1639–424. Epub 2019/03/15. PubMed PMID: 30885880.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gottlieb AB, Berman A, et al. The Efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase iib study of adults with active psoriatic arthritis. Arthritis Rheumatol. 2016;68(9):2163–2173. Epub 2016/04/10. PubMed PMID: 27059799.
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175–184; Epub 2007/01/04. PubMed PMID: 17200717; PubMed Central PMCID: PMCPMC1716210.
   PubMed Web of Science ®Google Scholar
• Stout RD, Jiang C, Matta B, et al. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol. 2005;175(1):342–349. Epub 2005/06/24. PubMed PMID: 15972667.
   PubMed Web of Science ®Google Scholar
• Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958–969. PubMed PMID: 19029990.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. Bethesda MNIoHNH, Lung and Blood Institute of Health; 2015. Available from: www.ginasthma.org.
   Google Scholar
• Adeniyi FB, Young T. Weight loss interventions for chronic asthma. Cochrane Database Syst Rev. 2012;7Cd009339. Epub 2012/07/13. https://doi.org/10.1002/14651858.CD009339.pub2. PubMed PMID: 22786526.
   Google Scholar
• Okoniewski W, Lu KD, Forno E. Weight loss for children and adults with obesity and asthma: a systematic review of randomized controlled trials. Ann Am Thorac Soc. 2019;16(5):613–625.
   PubMed Web of Science ®Google Scholar
• Watchorn D, Madden A, O’Shea D, et al. Weight loss in individuals with obesity and asthma. Ann Am Thorac Soc. 2019;16(7):933–934. PubMed PMID: 30969796.
   PubMedGoogle Scholar
• Shiraishi D, Fujiwara Y, Komohara Y, et al. Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Biochem Biophys Res Commun. 2012;425(2):304–308. Epub 2012/07/31. PubMed PMID: 22842565.
   PubMedGoogle Scholar
• Zhu T, Wu XL, Zhang W, et al.Glucagon like peptide-1 (GLP-1) modulates OVA-Induced airway inflammation and mucus secretion involving a protein kinase A (PKA)-dependent nuclear factor-kappaB (NF-kappaB) signaling pathway in mice. Int J Mol Sci. 2015;16(9):20195–20211. Epub 2015/09/08. PubMed PMID: 26343632; PubMed Central PMCID: PMCPMC4613197.
   PubMedGoogle Scholar
• Sutherland ER, Goleva E, King TS, et al. Cluster analysis of obesity and asthma phenotypes. PLoS One. 2012;7(5):36631.
   PubMed Web of Science ®Google Scholar
• Watchorn DC, Meurling J, Nolan G, et al. Inflammatory mediators in an asthmatic population on glp-1 analogue therapy for weight management. TP9 TP009 MECHANISTIC AND TRANSLATIONAL ASTHMA STUDIES. American Thoracic Society International Conference Abstracts: American Thoracic Society; 2021. p. A1424–A.
   Google Scholar
• Foer D, Beeler PE, Cui J, et al. Asthma exacerbations in type 2 diabetics with asthma on glucagon-like peptide-1 receptor agonists. Am J Respir Crit Care Med. 2020. https://doi.org/10.1164/rccm.202004-0993OC.
   Google Scholar
• Lee Y, Park Y, Kim C, et al. Longitudinal outcomes of severe asthma: real-world evidence of multidimensional analyses. J Allergy Clin Immunol Pract. 2021;9(3):1285–94.e6. Epub 2020/10/14. PubMed PMID: 33049391.
   PubMedGoogle Scholar
• Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140(1):162–92. Epub 2016/11/09. PubMed PMID: 27826098.
   PubMed Web of Science ®Google Scholar
• Moore WC, Kornmann O, Humbert M, et al. Outcomes following continuation or stopping long-term mepolizumab treatment in patients with severe eosinophilic asthma: the randomized comet trial. B93 Late breaking clinical trials in airway diseases. American Thoracic Society International Conference Abstracts: American Thoracic Society; 2020. p. A4211–A.
   Google Scholar
• Moore WC, Kornmann O, Humbert M, et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur Respir J. 2021. Epub 2021/06/27. https://doi.org/10.1183/13993003.00396-2021. PubMed PMID: 34172470.
   Web of Science ®Google Scholar
• Murphy K, Jacobs J, Bjermer L, et al. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 2017;5(6):1572–813. Epub 2017/11/11. PubMed PMID: 29122156.
   PubMed Web of Science ®Google Scholar
• McGregor MC, Krings JG, Nair P, et al. Role of biologics in asthma. Am J Respir Crit Care Med. 2018;199(4):433–445.
   Google Scholar
• Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med. 2021;385(18):1656–1668.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Gaga M, Inoue H, et al. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials. Lancet Respir Med. 2021;9(1):43–56. Epub 2020/09/28. PubMed PMID: 32979986
   PubMedGoogle Scholar
• Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989;170(6):2081–2095. Epub 1989/12/01. PubMed PMID: 2531194; PubMed Central PMCID: PMCPMC2189521.
   PubMed Web of Science ®Google Scholar
• Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170–181.
   PubMed Web of Science ®Google Scholar
• Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23–35.
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19(1):683–765. Epub 2001/03/13. PubMed PMID: 11244051.
   PubMedGoogle Scholar
• Trinchieri G. Interleukin-10 production by effector T cells: th1 cells show self control. J Exp Med. 2007;204(2):239–243. Epub 2007/02/12. PubMed PMID: 17296790.
   PubMed Web of Science ®Google Scholar
• Dowling JK, Afzal R, Gearing LJ, et al. Mitochondrial arginase-2 is essential for IL-10 metabolic reprogramming of inflammatory macrophages. Nat Commun. 2021;12(1):1460.
   PubMedGoogle Scholar
• Corraliza IM, Soler G, Eichmann K, et al. Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages. Biochem Biophys Res Commun. 1995;206(2):667–673. Epub 1995/01/17. PubMed PMID: 7530004.
   PubMed Web of Science ®Google Scholar
• Xu W, Ghosh S, Comhair SA, et al. Increased mitochondrial arginine metabolism supports bioenergetics in asthma. J Clin Invest. 2016;126(7):2465–2481. Epub 2016/05/24. PubMed PMID: 27214549; PubMed Central PMCID: PMCPMC4922712.
   PubMedGoogle Scholar
• Lewis ND, Asim M, Barry DP, et al. Arginase II restricts host defense to Helicobacter pylori by attenuating inducible nitric oxide synthase translation in macrophages. J Immunol. 2010;184(5):2572–2582. Epub 2010/01/26. PubMed PMID: 20097867; PubMed Central PMCID: PMCPMC2841360.
   PubMedGoogle Scholar
• Asosingh K, Lauruschkat CD, Alemagno M, et al. Arginine metabolic control of airway inflammation. JCI Insight. 2020;5(2). https://doi.org/10.1172/jci.insight.127801.
   Google Scholar
• Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384. Epub 2017/03/23. PubMed PMID: 28323260.
   PubMed Web of Science ®Google Scholar
• Kuperman DA, Schleimer RP. Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma. Curr Mol Med. 2008;8(5):384–392. Epub 2008/08/12. PubMed PMID: 18691065; PubMed Central PMCID: PMCPMC4437630.
   PubMedGoogle Scholar
• Wohlmann A, Sebastian K, Borowski A, et al.Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function. Biol Chem. 2010;391(2–3):181–186. Epub 2010/02/05. PubMed PMID: 20128689
   PubMed Web of Science ®Google Scholar
• Pernis AB, Rothman PB. JAK-STAT signaling in asthma. J Clin Invest. 2002;109(10):1279–1283. PubMed PMID: 12021241.
   PubMed Web of Science ®Google Scholar
• Ashino S, Takeda K, Li H, et al. Janus kinase 1/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses. J Allergy Clin Immunol. 2014;133(4):1162–1174. Epub 2013/12/22. PubMed PMID: 24365136.
   PubMed Web of Science ®Google Scholar
• Braithwaite IE, Cai F, Tom JA, et al. Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: a randomized, controlled, proof-of-activity trial. J Allergy Clin Immunol. 2021;148(3):783–789. Epub 2021/03/22. PubMed PMID: 33744327.
   PubMed Web of Science ®Google Scholar
• Siddiqui S, Bozik M, Archibald D, et al. Late breaking abstract - phase 2 trial evaluating the effects of dexpramipexole on blood eosinophils, lung function, and airway biomarkers in eosinophilic asthma. Eur Respir J. 2021;58(65):2900.
   Google Scholar
• Khurana S, Brusselle GG, Bel EH, et al. Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study. Clin Ther. 2019;41(10):2041–565. Epub 2019/08/27. PubMed PMID: 31447130.
   PubMed Web of Science ®Google Scholar
• Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742–51.e7. Epub 2018/10/26. PubMed PMID: 30359681.
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46–59. Epub 2018/11/13. PubMed PMID: 30416083.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10(1):11–25. Epub 2021/10/02. PubMed PMID: 34597534.
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-World effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496–506. Epub 2020/09/04. PubMed PMID: 32882249.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757–765. Epub 2019/12/24. PubMed PMID: 31866436.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Ponnarambil S, Downie J, et al. DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 2020;21(1):279.
   PubMedGoogle Scholar
• Ireland ASo. Pre-Budget Submission 2020 [cited 2022 Jan 29th]. Available from: https://www.asthma.ie/sites/default/files/files/document_bank/2020/Sep/ASI%20-%20Pre-Budget%20Submission%202021.pdf.
   Google Scholar
• Laba TL, Jan S, Zwar NA, et al. Cost-related underuse of medicines for asthma-opportunities for improving adherence. J Allergy Clin Immunol Pract. 2019;7(7):2298–306. Epub 2019/04/01. PubMed PMID: 30928659.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Zheng XY, Chung KF, et al. Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action. Lancet. 2016;388(10054):1939–1951. Epub 2016/10/19. PubMed PMID: 27751401.
   PubMed Web of Science ®Google Scholar
• Deaths Nro A. Why asthma still kills royal college of physicians. 2015 [cited 2022 Jan 29]. Available from: https://www.rcplondon.ac.uk/projects/outputs/why-asthma-still-kills.
   Google Scholar
• Hull JH. Not all wheeze is asthma: time for patients to exercise their rights. Thorax. 2015;70(1):7–8. Epub 2014/11/16. PubMed PMID: 25398497.
   PubMedGoogle Scholar
• Aaron SD, Boulet LP, Reddel HK, et al.Underdiagnosis and overdiagnosis of asthma. Am J Respir Crit Care Med.2018;198(8):1012–1020. Epub 2018/05/15. PubMed PMID: 29756989.
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Boulet LP, et al. Overdiagnosis of asthma in obese and nonobese adults. CMAJ. 2008;179(11):1121–1131. Epub 2008/11/19. PubMed PMID: 19015563; PubMed Central PMCID: PMCPMC2582787.
   PubMed Web of Science ®Google Scholar
• Cooper BG. An update on contraindications for lung function testing. Thorax. 2011;66(8):714.
   PubMed Web of Science ®Google Scholar